---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-039783"
form_type: "8-K"
ticker: "FATE"
cik: "0001434316"
company_name: "FATE THERAPEUTICS INC"
filed_at: "2023-08-08T23:59:59+00:00"
generated_at: "2026-06-12T01:30:05.736214+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Fate Therapeutics Q2 2023: cash $385M, FT522 Phase 1 start-up, FT825 IND planned 2H23

## Summary
- Cash position $385.2M as of June 30, 2023; runway into 2H25.
- Q2 2023 revenue $0.9M from ONO collaboration; GAAP op ex $63.5M incl $12.9M stock comp.
- Phase 1 start-up for FT522 ADR-armed CAR NK program; IND allowed May 2023.
- IND submission planned 2H23 for FT825/ONO-8250 HER2-targeted CAR T program under ONO collaboration.
- FT576 BCMA-targeted CAR NK and FT819 CD19-targeted CAR T programs enrolling patients in dose escalation.

## SEC filing metadata
- accession: 0000950170-23-039783
- form_type: 8-K
- ticker: FATE
- cik: 0001434316
- company_name: FATE THERAPEUTICS INC
- filed_at: 2023-08-08T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1434316/000095017023039783/0000950170-23-039783-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1434316/000095017023039783/fate-20230808.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-039783
- JSON: https://secwatch.observer/filing/0000950170-23-039783.json
- Plain text: https://secwatch.observer/filing/0000950170-23-039783.txt

## Key facts
- Earnings Releases
  FATE THERAPEUTICS INC reported second quarter ended June 30, 2023 results: revenue $0.9 million.
  - Period: second quarter ended June 30, 2023
  - Revenue: $0.9 million
  - Result: reported results
  source text: June 30, 2023 were $385.2 million. In addition, as of June 30, 2023, cash receivables from the Company’s collaboration with ONO were $2.8 million. • Total Revenue: Revenue was $0.9 million for the second quarter of 2023, which was derived from the Company’s conduct of preclinical development activities for a second collaboration candidate targeting an undisclosed
  evidence_url: https://www.sec.gov/Archives/edgar/data/1434316/000095017023039783/0000950170-23-039783-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.